Attovia Therapeutics
PublicAttovia Therapeutics is now publicly traded
The data on this page reflects Attovia Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Aug 4, 2026
Last Round
Series C
Apr 15, 2025
Total Funding Raised
$617.4M
Company Overview
Attovia Therapeutics operates in Biotech and is based in San Carlos, California. Its recorded funding history includes a Series C round in April 2025.
Attovia Therapeutics is a clinical-stage biotechnology company that develops precision biologics and multispecific therapeutics for immune-mediated diseases and oncology.
Sector
Biotech
Verticals
Life Sciences, Oncology
AI Layer
Non-AI
Attovia Therapeutics Comparables
Compare Attovia Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Zenas BioPharma | 84% | |
| Bambusa Therapeutics | 84% | |
| TriveniBio | 82% |
For institutional investors. Book with your work email.
Attovia Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Aug 4, 2026 | ||||
| Series C | Apr 15, 2025 | ||||
| Series B | May 9, 2024 | ||||
| Series A | Feb 8, 2024 | ||||
| Series A | Jun 20, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Attovia Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Series C, Series B |
| Redmile Group | Series B |
| Mirae Asset | Series C |
| Cormorant Asset Management | Series C, Series B |
| Vida Ventures | Series C |
| Deep Track Capital | Series C |
| Frazier Life Sciences | Series C, Series B, Series A |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- has_revenue_decreased_byNov 10, 2026
For the quarter, Attovia reports revenue down 100% compared with the same quarter last year.
- attends_eventSep 28, 2026
Attovia plans to present new clinical, translational, and preclinical data on ATTO-1310 and ATTO-2306 at the Fall Clinical Dermatology Conference 2026 in Nevada in Oct '26.
- attends_eventSep 28, 2026
Attovia presents new clinical, translational, and preclinical data on ATTO-1310 and ATTO-2306 at EADV 2026 in Austria in Sep '26 and at Fall Clinical Dermatology Conference 2026 in Nevada in Oct '26.
For institutional investors. Book with your work email.
Attovia Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.